TrialJCO precision oncology2026

Development and Validation of a Computational Histology Artificial Intelligence-Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials.

Christopher J Sweeney et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.